Vupanorsen shown to effectively decrease non-HDL cholesterol in patients already on statins: TRANSLATE-TIMI 70
Key Points: A need for various lipid-lowering agents to combat high cholesterol exists for those already taking statin medications. Vupanorsen is a monoclonal antibody... Read more.
Reduction in Lp(a) possible with siRNA therapy: APOLLO
Key Points: In the Phase I APOLLO study, patients without known ASCVD and elevated Lp(a) ≥150nmol/L were treated with a novel siRNA therapy (SLN360) in a single... Read more.
FAME 3 sub-study shows no difference in quality of life between FFR-guided PCI and CABG.
Key Points PCI has yet to be shown to be superior to CABG with respect to quality of life and angina in those with multivessel coronary artery disease. This substudy... Read more.
Effects of Diltiazem on Coronary Vasomotor Dysfunction: EDIT-CMD
Key Points: In the EDIT-CMD study, patients with coronary vasomotor dysfunction (encompassing both coronary vasospasm and microvascular dysfunction, as defined by... Read more.
More Improvement in Residual Angina and Quality of Life in Complete Revascularization.
Key Points The COMPLETE trial, published in 2019, demonstrated that in patients with ST-segment elevation myocardial infarction found to have multivessel disease,... Read more.
SODIUM-HF: Study Of Dietary Intervention Under 100 Mmol In Heart Failure
Key points: Sodium-HF sought to determine whether dietary sodium reduction reduces the morbidity or mortality associated with heart failure (HF) in the largest randomized... Read more.
An Old Drug with New Tricks: Tranexamic Acid Decreases Bleeding Events in Surgery, POISE-3 Suggests
Key Points: Tranexamic acid, given to patients undergoing noncardiac surgery, was associated with fewer bleeding events at 30 days. Participants of the POISE-3,... Read more.
VALOR-HCM: Treatment with mavacamten decreased need for septal reduction therapy in patients with hypertrophic cardiomyopathy.
Key Points: In the VALOR-HCM study, patients with severely symptomatic obstructive HCM on maximally tolerated medical therapy were treated with either mavacamten... Read more.
Stem Cells Did Not Decrease Heart Failure Readmissions in DREAM-HF
Key Points: In the DREAM-HF study, patients with persistent NYHA II-III HFrEF were treated with transendocardial mesenchymal precursor cells (MPCs) or a sham procedure.... Read more.
EMPULSE: Empagliflozin improves outcomes in all Heart Failure admissions
Key Points: In the EMPULSE study, patients admitted with acute HF of any ejection fraction with or without diabetes were treated with either empagliflozin or placebo.... Read more.